Dr. Emilie Seydoux, short biography
After studying biomedical sciences at the University of Fribourg and at the University of Bern, Dr. Emilie Seydoux obtained a PhD from the University of Bern in 2014. Her first line of research focused on the immune modulatory potential of engineered nanoparticles on different cell populations in the lung microenvironment. This work sparked Emilie's interest for vaccine research against infectious diseases of global importance. Working at the Infectious Disease Research Institute and the Fred Hutch Cancer Center in Seattle, USA, she collaborated on numerous projects aiming to optimize vaccine adjuvants and to understand their mechanisms of action, as well as developing vaccine candidates against pathogens that establish infections at mucosal surfaces such as the respiratory tract. Furthermore, Emilie worked during the acute phases of the COVID pandemic on the analysis of the cross-neutralizing B cell responses in human samples following SARS-CoV-2 infection or vaccination. Since joining the Lung Precision Medicine program of the DBMR in January 2022, she has worked on in vitro and in vivo models of intranasal vaccination.
Emilie has published a number of research articles, including the following selected publications:
Seydoux, E.; Wan, Y. H.; Feng, J.; Wall, A.; Aljedani, S.; Homad, L. J.; MacCamy, A. J.; Weidle, C.; Gray, M. D.; Brumage, L.; Taylor, J. J.; Pancera, M.; Stamatatos, L.; McGuire, A. T., Development of a VRC01-class germline targeting immunogen derived from anti-idiotypic antibodies. Cell Rep 2021, 35 (5), 109084. Link to publication
Seydoux, E.; Homad, L. J.; MacCamy, A. J.; Parks, K. R.; Hurlburt, N. K.; Jennewein, M. F.; Akins, N. R.; Stuart, A. B.; Wan, Y. H.; Feng, J.; Whaley, R. E.; Singh, S.; Boeckh, M.; Cohen, K. W.; McElrath, M. J.; Englund, J. A.; Chu, H. Y.; Pancera, M.; McGuire, A. T.; Stamatatos, L., Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. Immunity 2020, 53 (1), 98-105 e5. Link to publication
Orr, M. T.; Khandhar, A. P.; Seydoux, E.; Liang, H.; Gage, E.; Mikasa, T.; Beebe, E. L.; Rintala, N. D.; Persson, K. H.; Ahniyaz, A.; Carter, D.; Reed, S. G.; Fox, C. B., Reprogramming the adjuvant properties of aluminum oxyhydroxide with nanoparticle technology. NPJ Vaccines 2019, 4, 1. Link to publication
Liang, H.; Poncet, D.; Seydoux, E.; Rintala, N. D.; Maciel, M., Jr.; Ruiz, S.; Orr, M. T., The TLR4 agonist adjuvant SLA-SE promotes functional mucosal antibodies against a parenterally delivered ETEC vaccine. NPJ Vaccines 2019, 4, 19. Link to publication
Seydoux, E.; Liang, H.; Dubois Cauwelaert, N.; Archer, M.; Rintala, N. D.; Kramer, R.; Carter, D.; Fox, C. B.; Orr, M. T., Effective Combination Adjuvants Engage Both TLR and Inflammasome Pathways To Promote Potent Adaptive Immune Responses. J Immunol 2018, 201 (1), 98-112. Link to publication
Seydoux, E.; Rodriguez-Lorenzo, L.; Blom, R. A.; Stumbles, P. A.; Petri-Fink, A.; Rothen-Rutishauser, B. M.; Blank, F.; von Garnier, C., Pulmonary delivery of cationic gold nanoparticles boost antigen-specific CD4(+) T Cell Proliferation. Nanomedicine 2016, 12 (7), 1815-1826. Link to publication
|
